Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

L Klimek1, A M Chaker2, M Cuevas3

  • 1Zentrum für Rhinologie und Allergologie, Wiesbaden.

Laryngo- Rhino- Otologie
|May 27, 2021
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Graphene-plasmon-mediated coherent dynamics in an N-quantum-emitter system.

Optics express·2026
Same author

Correspondence: The First Biosimilar for Biologics in Allergy: CT-P39 (Omlyclo-Omalizumab-Igec) Is Available for Asthma, Chronic Spontaneous Urticaria, and Chronic Rhinosinusitis With Nasal Polyps.

Allergy·2026
Same author

[Use of Omalizumab-biosimilars for CRSwNP in the German Health Care System - a Position Paper of the German Societies for Allergy AeDA and ORL DGHNO-KHC].

Laryngo- rhino- otologie·2026
Same author

Correspondence: First Peanut (Arachis hypogaea) Allergen Oral Immunotherapy Product Out of Sale-A Major Drawback for Food Allergy Immunotherapy?

Allergy·2026
Same author

[Different immunological types of CRSwNP in the context of the new European EAACI nomenclature : Part 3: Hypersensitivity reactions of type VI].

HNO·2026
Same author

The Unmet Need of Olfactory Testing in Inflammatory Disorders of the Upper Airways-An EAACI Position Paper.

Allergy·2026
Same journal

Guideline-Based Cochlear Implant Care: A Model for Structuring Delegated Technical Aftercare.

Laryngo- rhino- otologie·2026
Same journal

Audiometric evaluation and quality-of-life in OSIA users - a retrospective monocentric study.

Laryngo- rhino- otologie·2026
Same journal

[Diagnosis and treatment of vestibular migraine - recent developments and future treatment strategies].

Laryngo- rhino- otologie·2026
Same journal

Laryngo- rhino- otologie·2026
Same journal

Laryngo- rhino- otologie·2026
Same journal

Laryngo- rhino- otologie·2026
See all related articles

The Sputnik COVID-19 vaccine uses adenoviral vectors for prime-boost vaccination. Concerns exist regarding data availability, potential risks in patient subgroups, and batch consistency, warranting further review.

Area of Science:

  • Vaccinology
  • Virology
  • Immunology

Background:

  • Adenoviral vector vaccines are crucial for addressing the SARS-CoV-2 pandemic.
  • The Sputnik (Gam-COVID-Vac) vaccine utilizes Ad26 and Ad5 vectors for prime-boost vaccination.
  • Incorporating the full SARS-Spike protein aims to elicit robust immune responses.

Purpose of the Study:

  • To evaluate the efficacy and safety of the Sputnik COVID-19 vaccine.
  • To address controversies and concerns regarding available clinical data and protocols.
  • To assess potential risks associated with adenoviral vector replication and batch variability.

Main Methods:

  • Review of published evidence from Phase II and early Phase III Sputnik vaccine studies.
  • Analysis of concerns raised by health authorities regarding data transparency and vaccine consistency.

Related Experiment Videos

  • Examination of potential risks in specific patient subgroups and implications of vector replication.

    • Main Results:

    • Published evidence is limited, with small sample sizes in early trials.
    • Full study protocols and clinical data for Sputnik have not been widely available.
    • Concerns regarding Ad5 vector replication and batch-to-batch reproducibility have been raised by regulatory bodies.

    Conclusions:

    • Further scrutiny of Sputnik vaccine data is needed due to limited transparency.
    • Potential risks for specific patient subgroups warrant investigation.
    • Approval by major health authorities like the EMA should be awaited pending comprehensive data review.